The multiple upcoming clinical catalysts across the pipeline could drive positive momentum for PRQR stock in the near term, particularly with target engagement data expected for AX-0810 in the current quarter.
Price Chart
Executive Summary
ProQR Therapeutics announced pipeline expansion and upcoming clinical catalysts at an investor event, including progress on its lead program AX-0810 and advancement of new programs AX-0811 and AX-0422. The company highlighted multiple clinical data readouts expected within its current cash runway, which extends into mid-2027.
Key Facts
- AX-0810 clinical target engagement data on track for H1 2026
- Biliary atresia selected as initial Phase 2 indication for AX-0810
- AX-0811 program advancing with CTA filing expected in mid-2026
- AX-0422 targeting Hurler syndrome with CTA filing expected in early 2027
- AX-2911 advancing toward first-in-human trial in China in H1 2027
- Company cash runway extends into mid-2027
Financial Impact
No specific financial figures disclosed
Risk Factors
- Clinical trials may not meet expectations
- Regulatory delays could impact timeline
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-040893 |
| Document: tm2611275d2_ex99-2.htm | 0001104659-26-040893 |
| Document: tm2611275d2_6k.htm | 0001104659-26-040893 |
| Document: 0001104659-26-040893-index-headers.html | 0001104659-26-040893 |
| Document: 0001104659-26-040893-index.html | 0001104659-26-040893 |
| Document: 0001104659-26-040893.txt | 0001104659-26-040893 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 23, 2026 4w ago | 6-K | $1.70 $1.66 | ▼ −2.35% | ▼ −1.68% | $1.24 (−27.06%) |
Sep 9, 2026 6w ago | 6-K | $1.99 $1.86 | ▼ −6.53% | ▼ −5.44% | $1.24 (−37.69%) |
Jul 16, 2026 14w ago | EFFECT | $1.67 $1.79 | ▼ −7.19% | ▼ −8.86% | $1.24 (+25.75%) |
Jun 25, 2026 17w ago | 6-K | $1.53 $1.81 | ▼ −18.30% | ▼ −16.13% | $1.24 (+18.95%) |
Jun 25, 2026 17w ago | 424B5 | $1.53 $1.81 | ▲ +18.30% | ▲ +16.13% | $1.24 (−18.95%) |
Jun 2, 2026 20w ago | 6-K | $1.47 $1.41 | ▼ −4.08% | ▼ −0.26% | $1.24 (−15.65%) |
May 12, 2026 23w ago | 6-K | $1.60 $1.51 | ▲ +5.63% | ▲ +5.70% | $1.24 (+22.50%) |
Apr 30, 2026 25w ago | 6-K | $1.57 $1.72 | ▲ +9.55% | ▲ +7.83% | $1.24 (−21.02%) |
Apr 30, 2026 25w ago | Press Release | $1.57 $1.72 | ▲ +9.55% | ▲ +7.83% | $1.24 (−21.02%) |
Apr 8, 2026 28w ago | 6-K | $1.98 $1.95 | ▼ −1.52% | ▼ −4.70% | $1.24 (−37.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers